NL-OMON33078已完成不适用
A Multiple Dose Study of the Safety and Pharmacology of LY2165766 - LY2165766 MAD study
Chorus LRL (Division of Eli Lilly)0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male 18 - 65
- •Healthy female 45 - 65 postmenopausal/sterilised
- •BMI 18.5 - 32
排除标准
- •Relevant medical history
研究者
相似试验
已完成
不适用
A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects with Hepatitis C InfectioHepatitis CNL-OMON41065Merck Sharp & Dohme (MSD)5
撤回
不适用
Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Paediatric Subjects with an Indwelling Central Venous CatheterVein blockage due to clot10014523Venous ThromboembolismNL-OMON36556Bristol-Myers Squibb4
已完成
不适用
Study of Varied Doses to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents with Hypertensio-I10 Essential (primary) hypertensionEssential (primary) hypertensionI10PER-008-05SANKYO PHARMA DEVELOPMENT,
已完成
1 期
To know the amount of the drug and safety of Brimonidine Tartarate ophthalmic suspensioCTRI/2019/03/018023Sun Pharma Advanced Research Company Limited13
进行中（未招募）
不适用
Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with wet Age-related Macular DegeneratioExudative Age-related Macular DegenerationMedDRA version: 14.1Level: LLTClassification code 10025411Term: Macular degeneration senileSystem Organ Class: 10015919 - Eye disordersEUCTR2011-002526-43-DEAllergan Limited204